Mizuho Securities Reaffirms Their Buy Rating on Avrobio (AVRO)
Mizuho Securities analyst Difei Yang maintained a Buy rating on Avrobio (AVRO) on September 12 and set a price target of $35.00. The company’s shares closed last Monday at $15.53.
According to TipRanks.com, Yang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.7% and a 33.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Revance Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Avrobio with a $27.67 average price target.
See today’s analyst top recommended stocks >>
Based on Avrobio’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $28.83 million. In comparison, last year the company had a GAAP net loss of $16.06 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.